S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:MGTX

MeiraGTx Competitors

$14.56
+0.66 (+4.75 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.58
Now: $14.56
$14.71
50-Day Range
$13.90
MA: $15.52
$16.43
52-Week Range
$8.82
Now: $14.56
$18.45
Volume131,708 shs
Average Volume113,151 shs
Market Capitalization$559.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Competitors

MeiraGTx (NASDAQ:MGTX) Vs. KYMR, ALVR, BCRX, VCEL, BLUE, and SRRK

Should you be buying MGTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to MeiraGTx, including Kymera Therapeutics (KYMR), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), and Scholar Rock (SRRK).

MeiraGTx (NASDAQ:MGTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for MeiraGTx and Kymera Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Kymera Therapeutics02402.67

MeiraGTx presently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Kymera Therapeutics has a consensus target price of $50.3333, suggesting a potential upside of 4.47%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than Kymera Therapeutics.

Profitability

This table compares MeiraGTx and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
Kymera TherapeuticsN/AN/AN/A

Institutional & Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares MeiraGTx and Kymera Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
Kymera TherapeuticsN/AN/AN/AN/AN/A

Kymera Therapeutics has lower revenue, but higher earnings than MeiraGTx.

Summary

MeiraGTx beats Kymera Therapeutics on 5 of the 8 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Valuation & Earnings

This table compares MeiraGTx and AlloVir's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
AlloVirN/AN/AN/AN/AN/A

AlloVir has lower revenue, but higher earnings than MeiraGTx.

Institutional & Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for MeiraGTx and AlloVir, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
AlloVir00403.00

MeiraGTx presently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 59.73%. Given MeiraGTx's higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than AlloVir.

Profitability

This table compares MeiraGTx and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
AlloVirN/AN/AN/A

Summary

MeiraGTx beats AlloVir on 4 of the 7 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and BioCryst Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
BioCryst Pharmaceuticals$48.83 million40.54$-108,900,000.00($0.94)-11.86

MeiraGTx has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
BioCryst Pharmaceuticals03802.73

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. BioCryst Pharmaceuticals has a consensus target price of $11.3750, suggesting a potential upside of 2.02%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts clearly believe MeiraGTx is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares MeiraGTx and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500.

Summary

MeiraGTx beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and Vericel's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
Vericel$117.85 million16.58$-9,660,000.00$0.18236.17

Vericel has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and Vericel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Vericel02602.75

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Vericel has a consensus target price of $49.00, suggesting a potential upside of 15.27%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts clearly believe MeiraGTx is more favorable than Vericel.

Profitability

This table compares MeiraGTx and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
Vericel0.12%0.13%0.10%

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Summary

Vericel beats MeiraGTx on 9 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and bluebird bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
bluebird bio$44.67 million43.11$-789,610,000.00($14.31)-2.00

MeiraGTx has higher earnings, but lower revenue than bluebird bio. MeiraGTx is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 3.6% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and bluebird bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
bluebird bio013402.24

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. bluebird bio has a consensus target price of $68.4667, suggesting a potential upside of 138.73%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than MeiraGTx.

Profitability

This table compares MeiraGTx and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
bluebird bio-256.84%-45.78%-35.14%

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Summary

bluebird bio beats MeiraGTx on 7 of the 13 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and Scholar Rock's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million42.08$-54,750,000.00($1.65)-8.82
Scholar Rock$20.49 million87.88$-51,000,000.00($1.85)-28.94

Scholar Rock has higher revenue and earnings than MeiraGTx. Scholar Rock is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 61.9% of Scholar Rock shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 24.6% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and Scholar Rock, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Scholar Rock00503.00

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Scholar Rock has a consensus target price of $61.60, suggesting a potential upside of 15.08%. Given MeiraGTx's higher probable upside, research analysts clearly believe MeiraGTx is more favorable than Scholar Rock.

Profitability

This table compares MeiraGTx and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
Scholar Rock-365.84%-80.16%-41.33%

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Summary

MeiraGTx beats Scholar Rock on 7 of the 13 factors compared between the two stocks.


MeiraGTx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
High Trading Volume
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74+1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07+1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83+3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56+17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39+0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83+2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10+5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75+2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41+3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80+3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11+3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13+2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19+6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02+1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76+1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54+2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18+0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20+1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50+4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21+3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60+9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40+6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30+1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
Curis logo
CRIS
Curis
1.3$9.47+3.6%$557.00 million$10 million-11.55Increase in Short Interest
Gap Up
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.3$21.00+2.7%$544.11 millionN/A-6.05
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$8.63+7.5%$533.51 millionN/A-1.26Upcoming Earnings
High Trading Volume
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.57+0.1%$512.46 million$4.36 million-4.74Upcoming Earnings
Increase in Short Interest
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.25+1.6%$469.42 millionN/A0.00Upcoming Earnings
HARP
Harpoon Therapeutics
1.5$17.65+8.4%$447.96 million$5.78 million-8.29Upcoming Earnings
News Coverage
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32+6.9%$412.63 millionN/A-3.43Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.